Tail risks get thinner

Investors entered the autumn with great anxiety about the trade war and Brexit. Those risks have abated, and so have flight-to-quality flows. Headline risk into yearend includes trade war news (US, China, EU) and soft US employment data. Yet we don’t see those derailing market trends.

  • Market Perspective

Highlights:

  • Investors entered the autumn with great anxiety about the trade war and Brexit. Those risks have abated, and so have flight-to-quality flows.
  • Headline risk into yearend includes trade war news (US, China, EU) and soft US employment data. Yet we don’t see those derailing market trends.
  • Equities continue to offer attractive earnings yields relative to bonds; it is hard to resist the appeal unless one fears a 2008- or 2011-like scenario.
  • For a similar duration, the EuroAggregate Corporate (IG) yields 50bp more than 6y Portugal (BBB). CSPP returns; we stay long Credit.
  • The USD is pulling back from the end-September peak. This too bodes well for risk conditions.

Download the full publication below

TAIL RISKS GET THINNER
DOWNLOAD
PDF
MORE INSIGHTS

RELATED INSIGHTS

READ NOW
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
READ NOW
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
READ NOW
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
MORE INSIGHTS